drugset / Trial / NCT00680160

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

NCT00680160

Phase 2 Completed 15 enrolled Pfizer
Open-labelTreatment

Summary

The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.

Timeline

Start
2006-04-30
Primary completion
2007-05-09
Completion
2007-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavaborole Small molecule 7.5 % Topical

Indications